Heron Therapeutics Inc vs State Street Real Estate Select Sector SPDR ETF — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while State Street Real Estate Select Sector SPDR ETF trades at $45.23. The key difference: State Street Real Estate Select Sector SPDR ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | XLRE | |
|---|---|---|
Market Cap | $91.46M | — |
Sector | Health | Sector/Thematic |
52-Week High | $1.96 | $45.46 |
52-Week Low | $0.39 | $40.01 |
Enterprise Value | $189.36M | — |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
XLRE, the Real Estate Select Sector SPDR ETF, trades at $45.23, down 0.42% on the day, while maintaining a bullish technical trend per moving averages. The fund's low 0.08% expense ratio and 3.4% trailing yield appeal to cost-conscious income investors. Recent news highlights a quiet revival in REIT ETFs, with XLRE gaining 11% year-to-date as of late May 2026, defying broader rate pressures amid shifting Fed expectations.
The outlook for XLRE is cautiously optimistic, supported by solid REIT fundamentals and potential as a geopolitical hedge. Key opportunities include attractive valuations and dividend sustainability, but risks persist from interest rate volatility and inflation concerns that could pressure real estate valuations and investor sentiment in the near term.
Trailing returns across standard periods
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →